Organon (OGN) Free Cash Flow (2020 - 2026)
Organon (OGN) recorded quarterly Free Cash Flow of $188.0 million in Q1 2026, up 95.83% quarter-over-quarter from $96.0 million in Q4 2025, and up 337.21% on a YoY basis from $43.0 million in Q1 2025.
Organon (OGN) Free Cash Flow (2020 - 2026) Analysis & Trends
Organon's Free Cash Flow history runs 7 years deep, the most recent figure standing at $188.0 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 337.21% year-over-year to $188.0 million; the TTM figure through Mar 2026 stood at $683.0 million (down 12.1% YoY), while the FY2025 annual figure was $538.0 million, down 29.58% from the prior year.
- Free Cash Flow was $188.0 million for Q1 2026 at Organon, up from $96.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $335.0 million in Q4 2024 to a low of -$44.0 million in Q2 2023.
- Historically, Free Cash Flow has averaged $158.8 million across 5 years, with a median of $181.0 million in 2025.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 1800.0% in 2022, then slumped 141.51% in 2023.
- A 5-year view of Free Cash Flow shows it stood at $204.0 million in 2022, then soared by 55.88% to $318.0 million in 2023, then gained by 5.35% to $335.0 million in 2024, then plunged by 71.34% to $96.0 million in 2025, then surged by 95.83% to $188.0 million in 2026.
- The last three Free Cash Flow figures came in at $188.0 million (Q1 2026), $96.0 million (Q4 2025), and $218.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 2.12 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 188.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188.00 Mn |
| Mar 31, 2026 | 188.00 Mn |
| Dec 31, 2025 | 96.00 Mn |
| Dec 31, 2025 | 96.00 Mn |
| Sep 30, 2025 | 218.00 Mn |
| Sep 30, 2025 | 218.00 Mn |
| Jun 30, 2025 | 181.00 Mn |
| Jun 30, 2025 | 181.00 Mn |
| Mar 31, 2025 | 43.00 Mn |
| Mar 31, 2025 | 43.00 Mn |
| Dec 31, 2024 | 335.00 Mn |
| Dec 31, 2024 | 335.00 Mn |
| Sep 30, 2024 | 99.00 Mn |
| Sep 30, 2024 | 99.00 Mn |
| Jun 30, 2024 | 300.00 Mn |
| Jun 30, 2024 | 300.00 Mn |
| Mar 31, 2024 | 30.00 Mn |
| Mar 31, 2024 | 30.00 Mn |
| Dec 31, 2023 | 318.00 Mn |
| Dec 31, 2023 | 318.00 Mn |